ypertension was once a rarity in children, affecting less than 1% of the pediatric population. Now, with rates on the rise, hypertension is estimated to affect approximately 3.6% of children in the United States.
of renin and aldosterone, which are known to increase the risk of hypertension. 3 Elevated levels of renin can lead to severe hypertension and endothelial dysfunction, whereas elevated levels of aldosterone cause increased sodium reabsorption, fluid retention, and, ultimately, elevated blood pressure (BP). Prior patient history of urinary tract infection or unexplained fevers can be suggestive of pyelonephritis, renal cortical scars, and reflux nephropathy. 4 Vesicoureteral reflux is common in children. Although it generally dissipates and improves over time, it can lead to hypertension, chronic kidney disease, and, rarely, end-stage renal disease. 5 Other common secondary causes of hypertension in children younger than 10 years include coarctation of the aorta, patent ductus arteriosus, pain, neuroblastoma, hyperaldosteronism, and hyperthyroidism. 4 Clinicians should consider and thoroughly explore secondary causes when diagnosing hypertension in children. They should complete an extensive history and physical examination, collecting pertinent information, including medical history, family history, and social history. 4 Another possible explanation for hypertension can include use of medications known to raise BP (Table 1) . Additional considerations should be explored if no cause for hypertension is determined after a thorough history and physical examination have been completed and can include the following tests 4 
:
• Urine toxicology-rule out illicit drug use • Plasma and urine steroid levels-rule out steroid-mediated hypertension • Plasma metanephrines-rule out pheochromocytoma • Polysomnography-rule out obstructive hypertension • 24-hour ambulatory BP monitoring-rule out white coat hypertension • Renal arteriogram with venous renin sampling-rule out renal artery stenosis
Definition and Diagnosis
The process of defining and diagnosing hypertension is more challenging in children than in adults. According to a report from the Joint National Committee on prevention, detection, evaluation, and treatment of high BP, 6 prehypertension in adults is defined as having 2 BP readings greater than 120/80 mm Hg and hypertension is defined as 2 blood pressure readings greater than 140/90 mm Hg. 7 In contrast, pediatric hypertension is based on the normative distribution of BP in healthy children with the following definitions 6 : -Normal BP is a systolic BP (SBP) and diastolic BP (DBP) less than the 90th percentile for sex, age, and height. -Prehypertension is classified as an average SBP or DBP greater than or equal to the 90th percentile, but less than the 95th percentile. Children and adolescents with BP levels at 120/80 mm Hg or above, but less than the 95th percentile, should be considered prehypertensive. -Hypertension in children is defined as an average SBP or DBP greater than or equal to the 95th percentile for sex, age, and height on at least 3 separate occasions. -Severe hypertension is an average SBP or DBP greater than or equal to the 99th percentile for sex, age, and height.
Routine BP monitoring in children younger than 3 years is not recommended unless they have comorbid conditions, such as renal artery stenosis, vesicoureteral reflux, or pyelonephritis, which may place them at risk of hypertension. The preferred method of BP measurement is auscultation using a standard clinical sphygmomanometer with stethoscope and an ageand size-appropriate cuff. Elevated BP must be confirmed on repeated visits before a diagnosis can be made. 6 The National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents 6 has created a chart with normal distributive BPs based on age, sex, and height that can be used to determine whether children are A strong correlation exists between weight and BP, and weight loss in overweight patients has been associated with a decrease in BP. 6 Weight loss reduces BP and also decreases BP sensitivity to salt and other cardiovascular risk factors. 6 In addition to weight loss and exercise, education is another effective tool for controlling BP in children who are hypertensive. Education provides families with the knowledge necessary to help their children achieve weight loss and use behavior modification techniques that reduce sedentary activity over a period of time. 6 Although not all children participate in sports, an effort should be made to help identify physical activities they enjoy and encourage them to partake in them for 30 to 60 minutes daily. Children who have an understanding of the importance of maintaining 30 to 60 minutes of physical activity daily are more likely to become proactive in their treatment and self-monitor their physical activities. If nonmedical therapies do not result in goal BP, medical therapy would then be warranted.
Medications

Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE) inhibitors exact their effect by inhibiting the conversion of angiotensin I to angiotensin II, which plays a major role in arterial BP regulation. Angiotensin II is a potent vasoconstrictor and also stimulates aldosterone secretion. The release of aldosterone facilitates sodium and water reabsorption, as well as potassium loss. The blocking of the ACE results in vasodilation and decreases aldosterone, ultimately reducing BP. Angiotensin-converting enzyme inhibitors have been shown to reduce the decline of glomerular filtration rate in adult patients with nondiabetic nephropathy, and this beneficial effect is extrapolated to children. 8 Angiotensin-converting enzyme inhibitors likely reduce risk of nephropathy by lowering intraglomerular pressure, which decreases filtration pressure, decreases proteinuria, and prevents further deterioration in renal function. 8 Many of the ACE inhibitors have been clinically tested in children and are shown to be safe and effective. As is the case with most antihypertensive medications, ACE inhibitors have demonstrated a dose-dependent lowering of BP with Food and Drug Administration-approved dosing ranges that can be found in the package inserts. 3 At this time, no ACE inhibitor has shown superiority over another, and the choice of ACE inhibitor is based on several factors, including frequency, formulation, patient response, and provider preference. Adverse effects that can be seen with ACE inhibitors include hypotension, hyperkalemia, angioedema, dry cough, increases in serum creatinine and blood urea nitrogen levels, and rarely, acute renal failure. Angioedema is the most severe adverse effect caused by ACE inhibitors, with an incidence of 0.1% to 0.2% and can occur at any point during therapy. 8 The inhibitor-induced angioedema can be a life-threatening situation, requiring urgent care.
Angiotensin Receptor Blockers
Angiotensin receptor blockers (ARBs) block the binding of angiotensin II to its receptor, preventing vasoconstriction. Antagonizing the angiotensin II receptor allows vessel dilation, aldosterone antagonism, and similar to ACE inhibitors, reduction in intraglomerular pressure. The main use for ARBs in pediatrics is for chronic renal diseases with or without hypertension when ACE inhibitors do not work effectively. 9 Angiotensin receptor blockers have been shown to effectively reduce BP in a dose-related manner in children. In trials where irbesartan, losartan, and candesartan were evaluated, these 3 agents showed significant reductions in BP when compared with placebo. 9 Common adverse effects for ARBs include cough, rhinitis, headache, dizziness, blurred vision, and fatigue. Elevated potassium levels can result from the prevention of aldosterone production, similar to ACE inhibitors, and should be monitored regularly during therapy.
Aliskiren
Aliskiren is the first oral medication belonging to a new drug class that directly inhibits the enzyme renin. 10 Renin is the starting point of the renin-angiotensin-aldosterone system and enzymatically converts angiotensinogen to angiotensin I, which is subsequently converted to angiotensin II, causing elevated BP and aldosterone release. The place for aliskeren in the pediatric population is not fully understood yet, because aliskeren is a relatively new medication with limited use so far.
β-Blockers
Prior to the introduction of ACE inhibitors and ARBs, β-blockers were once the mainstay of therapy for the treatment of hypertension in children. In children and adults, β-blockers have a wide range of use for indications such as myocardial infarction, angina, congestive heart failure, and migraines. The mechanism by which these drugs lower BP is not fully understood, but their negative chronotropic and inotropic effects on the heart reduce cardiac output, and this mechanism is believed to account for their antihypertensive effects. β-Blockers also have been shown to reduce renin activity and reduce vasoconstriction. 11 The few β-blockers that have been studied in children include propranolol, atenolol, metoprolol, bisoprolol, and labetalol. Differences between these agents are mainly due to their selectivity in antagonizing cardiac β receptors, lipid solubility, intrinsic sympathomimetic activity (ability to also agonize adrenergic receptors), and potency. 11 Propranolol is a nonselective β-blocker, was the first available in the United States, and is the most widely used in children and adolescents. 12 It is safe, well-tolerated, and able to effectively decrease SBP, DBP, heart rate (HR), and cardiac contractility in adolescents with minimal adverse effects. 12 Since propranolol is not cardioselective, it can block β2-receptors within the lungs, causing bronchoconstriction, and is thus contraindicated in patients with asthma. Atenolol, metoprolol, and bisoprolol are cardioselective β-blockers that are able to effectively reduce SBP, DBP, and HR. Labetalol differs from the previously discussed β-blockers because of its antagonistic activity on β and peripheral α receptors as well. Labetalol has been shown to be effective in reducing BP in patients unresponsive to other β-blockers. β-Blockers have a tendency to cause severe bradycardia, fatigue, and orthostatic hypotension, placing patients at risk for syncope and falls. When initiating patients on a β-blocker, clinicians must start with low weight-based dosing and titrate to the desired BP in an effort to prevent pronounced bradycardia.
Calcium Channel Blockers
Calcium channel blockers (CCBs) reduce stimulation of myocardial and vascular smooth muscle through inhibition of calcium-dependent slow channels within the cellular membrane. The 2 classes of CCBs are tertiary amines and dihydropyridines. The tertiary amines are mainly used as antiarrhythmic agents because of their ability to more selectively act on myocardial cells and for the purpose of this review are not discussed. The dihydropyridines, however, have significant BP-lowering effects as a result of their ability to dilate peripheral arterioles and reduce peripheral vascular resistance. Calcium channel blockers used in pediatric patients include amlodipine, nifedipine, isradipine, and felodipine.
Amlodipine is the most commonly used CCB in children because of its ability to effectively reduce BP, minimal adverse effect profile, and once-daily dosing, which is due to its prolonged action. In a study of 268 patients conducted by Flynn et al, 14 amlodipine effectively reduced SBP with both the 2.5-mg and 5-mg dose in patients 6 to 16 years of age. Nifedipine is equally effective at lowering BP in pediatric patients but comes in an extended release tablet that is unable to be crushed or chewed and may be difficult for some children to swallow. 8 Isradipine also is effective in treating pediatric hypertension but requires multiple daily doses. Finally, felodipine did not show significant reductions in SBP in children 6 to 16 years of age, but it did show a significant reduction of DBP in this population when evaluated. 15 As a class, CCBs are well-tolerated but are commonly associated with hypotension, fatigue, and reflexive tachycardia, which dissipate after a few weeks of treatment. Peripheral edema and gingival hyperplasia can be seen with these agents, and all patients should be educated on the importance of dental hygiene when taking a CCB.
Diuretics
Diuretics lower BP by reducing plasma volume and peripheral vascular resistance through inhibition of sodium and water reabsorption by the kidney. 8 Three classes of diuretics are used in the treatment of hypertension: thiazide, loop, and potassium-sparing diuretics. Thiazide diuretics have a long history of safety and efficacy in adults and are recommended as first-line therapy for most adult patients with hypertension. On the basis of their safety and efficacy in adults, low-dose thiazide diuretics are assumed to have similar benefit in pediatric patients. 6 Hydrochlorothiazide enhances the effects of many other antihypertensive agents (ACE inhibitors and ARBs) and may be preferred because of once-daily dosing.
Loop diuretics such as furosemide, torsemide, and bumetanide are usually dosed once to twice daily and are useful in patients with resistant hypertension, underlying renal disease, or fluid retention. 10 The potassium-sparing diuretics, spironolactone, triamterene, and amiloride, have the risk of hyperkalemia. Periodic monitoring of potassium levels is therefore recommended, especially if patients are taking concomitant medications that can increase serum potassium levels (ie, ACE inhibitors and ARBs). 10 Additional adverse effects of spironolactone include gynecomastia, breast tenderness, amenorrhea, and irregular menses, which are undesirable for most patients. 16 Patients receiving diuretics require laboratory monitoring after initiation and dose changes due to possible electrolyte disturbances, glucose intolerance, and adverse lipid effects. 17 Because of the lack of controlled studies examining the use of diuretics in pediatric hypertension, they are recommended as add-on therapy and for children who present with edema and/or are resistant to first-line treatment options. 8, 17, 18 Additional Agents
In addition to the agents discussed earlier, central α-adrenergic agonists, peripheral α-antagonists, and vasodilators can be used to treat pediatric hypertension. These antihypertensive agents are considered when BP is not controlled with firstline medications due to limited data on their use in children. 8 Most evidence is based on expert opinion, and clinicians are recommended to initiate with low doses and titrate up to effect until maximal doses are obtained or the patient experiences adverse effects.
Clonidine, an α-adrenergic agonist, simulates α2-adrenergic receptors that decrease central sympathetic outflow, peripheral vascular resistance, and HR. Clonidine comes in an oral and transdermal formulation, which is a weekly patch. 19 Adverse effects of clonidine include bradycardia, dry mouth, sedation, dermatitis with patch administration, and rebound hypertension with abrupt discontinuation of oral tablets. To avoid rebound hypertension, clinicians must taper the dose of clonidine gradually over the course of several days. 19 The peripheral α-antagonists prazosin, terazosin, and doxazosin inhibit postsynaptic α1-adrenergic receptors, which results in vasodilation of veins and arterioles, decreasing total peripheral resistance and BP. 8 These agents have large adverse effect profiles that include syncope with first dose, orthostatic hypotension, palpitations, urinary frequency, and drowsiness, which limit their use in children.
Peripheral vasodilators include minoxidil and hydralazine, which exert their BP-lowering effects by relaxing arterial smooth muscle. Adverse effects of minoxidil include fluid retention and reflex tachycardia, and prolonged use can cause hypertrichosis. 20 Palpitations, reflex tachycardia, and a lupus-like syndrome can be seen with hydralazine use. 21 Minoxidil has the most data to support its use in the pediatric setting, although most of the studies included small sample sizes. These agents are reserved for add-on therapy for hypertension resistant to treatment with multiple antihypertensive agents and should be used with caution because of their adverse effects. 8, 18 Selecting Agents for Pediatric Hypertension Selection of an agent to treat pediatric hypertension is similar to that for adults in that compelling indications (chronic kidney disease, diabetes, asthma, etc) are first assessed and indication-appropriate medications are initiated. If no compelling indications requiring diseasestate specific BP drug therapy are present, firstline agents in children usually consist of ACE inhibitors or ARBs, because of their ability to effectively decrease BP and their relatively limited adverse effect profiles. Many ACE inhibitors have once-daily dosing, which allows for better adherence in pediatric patients.
If patients do not respond or are intolerant to ACE inhibitor or ARB therapy, β-blockers and CCB are next-line agents, and the decision for choosing an agent is based on patient parameters, physician's preference, adverse effect profile, and ease of dosing and administration. From that point, if other medications need to be used to control BP, the choice between diuretics and peripheral vasodilators is largely made on need for fluid removal or more aggressive control of BP. These medications are effective at lowering BP; however, they come with significantly more adverse effects, which limit their use in children. A full list of the medications discussed, their doses and frequencies, and common adverse effects is provided in Table 2 .
Treatment of Hypertensive Crises
Hypertensive emergencies in children are rare and traditionally have been due to secondary underlying disease. 23 Hypertensive crises are further broken down into hypertensive urgency and hypertensive emergency (Table 3) . 24 When patients have hypertensive crises, they must receive prompt treatment to safely lower BP, prevent further symptoms, and cease the progression of end-organ damage.
Most published literature for pediatric hypertension focuses on the epidemiology and management of general hypertension, with little focus on severe hypertension. In the adult population, approximately 1% of the hypertensive population is estimated to have a hypertensive crisis at some point during their lives. 25 Because of the secondary nature of hypertension in children younger than 10 years, the prevalence of hypertensive crises in children may be higher. In a retrospective study from one center, 35 of 246 children (14.2%) who were admitted with hypertension had severe hypertension with complications. 26 This number likely overrepresents the true incidence of hypertensive crises in pediatrics, but implies it is possibly more common in children than in adults.
The management of hypertensive crises involves prompt and controlled lowering of BP. Treatment goals are based on adult data in which the mean arterial pressure should be reduced by 25% of the planned BP reduction over the first 8 to 12 hours, a further 25% over the next 8 to 12 hours, and the final 50% over the 24 hours following that. 24 The intent of slowly reducing BP is to prevent hypoperfusion to vital organs that can lead to infarction and permanent damage.
In patients with hypertensive urgency who are asymptomatic without evidence of endorgan injury, oral medications can be used to gradually lower BP to the desired goal. 23 Intravenous antihypertensive agents are used in emergency situations because of the need to more quickly lower BP to prevent further progression of end-organ damage. Patients in hypertensive emergency will be admitted to the intensive care unit with invasive hemodynamic monitoring, allowing for careful titration of intravenous antihypertensive agents. The use of intravenous boluses is not recommended because of an increased risk of hypotensive complications and permanent neurological sequelae when compared to continuous infusions. 23 Please see Figure 1 for an algorithm of medications used in hypertensive crisis.
Most agents for hypertensive crisis have already been discussed, with the exceptions of nicardipine and fenoldopam. Nicardipine is an intravenous dihydropyridine CCB used as a first-line agent for hypertensive emergencies, and it is able to reduce peripheral vascular resistance without negatively affecting inotropic ability of the heart. It has a short onset of action and half-life, about 15 minutes each. 23 Fenoldopam produces rapid vasodilation by selectively agonizing dopamine 1 receptors with moderate activity on α-adrenergic receptors, which allows it to increase renal blood and urinary flow, which induces natriuresis. 23 Nurses' Role in the Care of Treating Children With Hypertension
In the inpatient setting, nurses play a crucial role in prescribing antihypertensives, BP monitoring, and medication delivery, which is especially true for patients in hypertensive crises requiring invasive hemodynamic motoring and continuous infusion medications in the intensive care unit. The nurse's responsibility in this setting is to be knowledgeable of the medications in regard to their mechanism of action, onset, duration, and need for titration and weaning based on BP measurements. As nurses gain knowledge of and experience with BP medications, they will be able to better evaluate the appropriateness of therapy and instructions for administration and titration, which will aid in optimized care as nurses are the last line of defense before and after patients receive medications. Because of the risk of hypotension and further deleterious consequences from intravenous antihypertensive agents, nurses should never hesitate to consult with physicians and pharmacists on questions about the medications, indications, dosing, administration with other medications, and adverse effects. If something seems questionable, ask questions.
Nurses are able to build strong bonds with their patients, especially children. They are encouraged to advocate behavior modification in regard to diet, physical activity, weight, and stress. These discussions should provide explanations of why these modifications are crucial. Without the why, children are less likely to understand the importance of these interventions, which will ultimately result in nonadherence with their antihypertensive therapy. Education should be provided to both the patient and the parents and include how the medication works, how to take the medication, and potential adverse effects. With the nursing profession adding a holistic and psychosocial approach to caring for patients, children tend to respond with attention and inquisition, thus placing nurses in a pivotal position to facilitate these conversations.
Conclusion
Hypertension affects at least 3% of the pediatric population, and if obesity and diabetes rates continue to climb, hypertension rates are likely to increase as well. Medications for the treatment of hypertension are selected on the basis of compelling indications, safety and efficacy, formulation, and ease of administration. In treating hypertensive crises, oral medications are used in urgent situations, whereas intravenous drugs are used in the setting of emergencies in which end-organ damage is possible. Nurses play a vital role in the treatment of hypertension in children through medication delivery, ongoing BP monitoring, and communication with physicians, parents, and patients.
